Bristol holds option to acquire F-star Alpha and its FS102; withdrawn
Executive Summary
Bristol-Myers Squibb Co. received the exclusive option to acquire F-star Alpha Ltd. BMS may exercise the option when and if it decides to proceed with a Phase IIb trial for F-star Alpha's preclinical antibody FS102 for HER2-positive breast and gastric cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice